Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eprenetapopt + azacitidine
- Development stage
- Phase 3
- Lead developer
- Aprea Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Eprenetapopt (APR-246) is a first-in-class small molecule developed by Aprea Therapeutics that restores wild-type p53 functions in TP53-mutant cells by restoring the protein's conformation and function. This combination therapy pairs eprenetapopt with azacitidine, a hypomethylating agent, for the treatment of TP53-mutant myelodysplastic syndromes (MDS). The combination was evaluated in a pivotal Phase 3 trial (ASPIRE) but failed to meet its primary endpoint of complete response rate compared to azacitidine alone. Despite this, the combination has previously received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for MDS.
- Other names
- APR-246 + azacitidineeprenetapopt + azacitidine
02
Targets
DNMT (DNA methyltransferase)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on eprenetapopt + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eprenetapopt + azacitidine.